10-Q: Intuitive Surgical Revenue Jumps 23% in Q3

Intuitive Surgical's Q3 revenue increased 23% year-over-year, driven by procedure growth and system placements.

Summary

• Total revenue increased 23% to $2.51 billion in Q3 2025, compared to $2.04 billion in Q3 2024.
• Da Vinci procedures grew 19% to approximately 797,000 in Q3 2025.
• Ion procedures grew 52% to approximately 37,900 in Q3 2025.
• Instruments and accessories revenue increased 20% to $1.52 billion.
• Systems revenue increased 33% to $590 million.
• 427 da Vinci systems were placed in Q3 2025, including 240 da Vinci 5 systems.
• The installed base of da Vinci systems reached approximately 10,763, a 13% increase year-over-year.
• Gross profit margin was 66.4% in Q3 2025, compared to 67.4% in Q3 2024.
• Operating income increased 32% to $760 million.
• The company repurchased 4.0 million shares for $1.92 billion during the quarter.
• Cash, cash equivalents, and investments totaled $8.43 billion as of September 30, 2025.

Sentiment

Score: 8

Explanation: The filing is generally positive, with strong revenue and procedure growth. However, there are some concerns about gross margin, competition, and macroeconomic factors.

Positives

• Total revenue increased by 23% year-over-year, indicating strong demand for Intuitive Surgical's products and services.
• Da Vinci procedures grew by 19%, demonstrating continued adoption of robotic-assisted surgery.
• Ion procedures grew by 52%, showing increasing utilization of the Ion endoluminal system.
• Systems revenue increased by 33%, driven by higher system placements and ASPs.
• The company placed 240 da Vinci 5 systems, indicating strong demand for the new generation system.
• The installed base of da Vinci systems grew by 13%, providing a larger base for recurring revenue.
• Operating income increased by 32%, reflecting improved profitability.
• The company has a strong cash position with $8.43 billion in cash, cash equivalents, and investments.

Negatives

• Gross profit margin decreased from 67.4% to 66.4%, primarily due to the impact of tariffs.
• The number of U.S. da Vinci bariatric procedures performed declined in the high-single digits.
• System demand in China has been adversely impacted by increasing robotic-assisted surgical system competition from domestic companies and, to a lesser extent, a broader central government focus on systematic governance.
• The company experienced isolated stresses to supply, particularly for specific component materials impacted by evolving trade requirements and at certain subcontract suppliers that were operationally challenged to meet production requirements.

Risks

• Macroeconomic and geopolitical factors, including tariffs, trade barriers, supply chain challenges, inflationary pressures, and elevated interest rates, could materially adversely affect the company's results of operations and liquidity.
• Hospitals continue to experience challenges with staffing and cost pressures that could affect their ability to provide patient care.
• The company faces increasing competition from other companies in the field of robotic-assisted medical procedures.
• The company's future sales in China are uncertain due to competition and governmental actions.
• The company may face increased pricing pressure in China due to limits on what hospitals can charge patients for surgeries using robotic surgical technology.
• The company is subject to increasingly stringent medical device, privacy, and other regulations.
• The company may be exposed to defaults under its lease financing arrangements if its customers are adversely affected by economic pressures or uncertainty, changes in healthcare laws, coverage and reimbursement, or other customer-specific factors.
• Third parties have offered, and may continue to offer, instruments that have been modified to support the use of some of the company's limited-use instruments beyond their labeled life, which could result in reduced revenue and negative publicity.

Future Outlook

The company expects that future placements of da Vinci surgical systems will be impacted by a number of factors, including supply chain risks; economic and geopolitical factors; the trade environment; inflationary pressures; high interest rates; hospital staffing shortages; procedure growth rates; evolving system utilization and point-of-care dynamics; capital replacement trends; additional reimbursements in various global markets, such as in Japan; the timing around governmental tenders and authorizations, as well as governmental actions impacting the tender process, such as the governance campaign in China; hospitals response to the evolving healthcare environment; the timing of when the company receives regulatory clearance in its other OUS markets for its da Vinci 5, da Vinci X, da Vinci Xi, and da Vinci SP surgical systems and related instruments; and the market response.

Management Comments

• The company seeks to demonstrate that its products can deliver better outcomes that are validated by rigorous peer-reviewed evidence.
• The company aims to work with clinicians and care teams to create better patient experiences that enable patients to more quickly get back to what matters most in their lives, with fewer complications, less pain and discomfort, and greater predictability.
• The company aims to enable the care teams who use its platforms and technology-enabled ecosystem to have better experiences that augment their skills while reducing fatigue and increasing efficiency and reliability.
• The company aims to help lower the total cost of care per patient episode when compared with existing treatment alternatives, providing a return on investment for hospitals and healthcare systems and value for payers.
• The company aims to expand access to high-quality minimally invasive care by partnering with hospitals, healthcare systems, and patient advocacy groups to address barriers to care.

Industry Context

The medical device industry is highly competitive and subject to rapid technological change. Intuitive Surgical faces competition from companies offering products for open or MIS surgeries, companies providing other therapeutic approaches for target clinical conditions, and companies developing diagnostic solutions that could serve as alternatives to current or planned Intuitive offerings. The company's success depends on its ability to innovate and develop new products and services that meet the needs of surgeons and patients.

Comparison to Industry Standards

• Medtronic, a major player in the medical device industry, has been actively developing its own robotic surgery platform to compete with Intuitive Surgical's da Vinci system.
• Johnson & Johnson has also entered the robotic surgery market with its Ottava system, posing a significant competitive threat to Intuitive Surgical.
• Smaller companies like CMR Surgical and Distalmotion are also developing robotic surgery systems, offering alternative solutions to Intuitive Surgical's products.
• Intuitive Surgical's da Vinci system has a well-established track record and a large installed base, giving it a competitive advantage over newer entrants in the market.
• The company's focus on innovation and its comprehensive ecosystem of products and services also differentiate it from its competitors.

Legal Proceedings

• The Company is currently named as a defendant in a number of individual product liability lawsuits filed in various state and federal courts.
• On October 19, 2022, a jury rendered a verdict against the Company awarding $10 million in damages to Rex Medical, L.P. in a patent infringement lawsuit. On October 2, 2025, the Court of Appeals affirmed the district courts judgment on all appealed issues.
• On May 10, 2021, Surgical Instrument Service Company, Inc. (SIS) filed a complaint in the Northern District of California Court alleging antitrust claims against the Company relating to EndoWrist service, maintenance, and repair processes. On February 27, 2025, SIS filed a Notice of Appeal to the Ninth Circuit Court of Appeals.
• Three class action complaints were filed against the Company in the Northern District of California Court alleging antitrust allegations relating to the service and repair of certain instruments manufactured by the Company. On March 31, 2025, the Court granted plaintiffs motion for class certification.
• On September 18, 2024, Restore Robotics Repairs (Restore) filed a complaint in the United States District Court for the Northern District of Florida alleging antitrust claims against the Company relating to the service and replacement of X/Xi EndoWrist instruments for use with the da Vinci X and Xi surgical systems.

Stakeholder Impact

• Shareholders: The strong financial results and share repurchase program are positive for shareholders.
• Employees: The company's growth and profitability are positive for employees.
• Customers: The company's innovative products and services are positive for customers.
• Patients: The company's products and services have the potential to improve patient outcomes.
• Suppliers: The company's growth is positive for suppliers.

Next Steps

• Continue to expand procedure adoption and acceptance of products.
• Continue to invest in commercial operations, product development activities, facilities, and intellectual property.
• Continue to monitor and mitigate supply chain risks.
• Continue to monitor and respond to competition.
• Continue to monitor and comply with regulations.

Key Dates

Recommendation

Intuitive Surgical's strong Q3 results, driven by procedure growth, system placements, and innovation, make it a compelling investment. The company's dominant market position, recurring revenue model, and strong cash position support a strong buy recommendation.

Keywords

Intuitive Surgical, da Vinci, robotic surgery, revenue, procedures, systems, Ion, financial results, SEC filing